BRPI0820210A2 - compound, pharmaceutical composition, use of a compound, and method of therapeutic treatment of a mammal. - Google Patents

compound, pharmaceutical composition, use of a compound, and method of therapeutic treatment of a mammal.

Info

Publication number
BRPI0820210A2
BRPI0820210A2 BRPI0820210A BRPI0820210A BRPI0820210A2 BR PI0820210 A2 BRPI0820210 A2 BR PI0820210A2 BR PI0820210 A BRPI0820210 A BR PI0820210A BR PI0820210 A BRPI0820210 A BR PI0820210A BR PI0820210 A2 BRPI0820210 A2 BR PI0820210A2
Authority
BR
Brazil
Prior art keywords
compound
mammal
pharmaceutical composition
therapeutic treatment
therapeutic
Prior art date
Application number
BRPI0820210A
Other languages
Portuguese (pt)
Inventor
Westman Jacob
Malm Johan
Wannberg Johan
Nekhotiaeva Natalia
Bäckman Ulrika
Original Assignee
Clanotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clanotech Ab filed Critical Clanotech Ab
Publication of BRPI0820210A2 publication Critical patent/BRPI0820210A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
BRPI0820210A 2007-11-15 2008-11-14 compound, pharmaceutical composition, use of a compound, and method of therapeutic treatment of a mammal. BRPI0820210A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98814707P 2007-11-15 2007-11-15
EP07120799 2007-11-15
PCT/EP2008/065596 WO2009063070A2 (en) 2007-11-15 2008-11-14 Quinoline derivatives and their use as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0820210A2 true BRPI0820210A2 (en) 2017-05-09

Family

ID=39295948

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820210A BRPI0820210A2 (en) 2007-11-15 2008-11-14 compound, pharmaceutical composition, use of a compound, and method of therapeutic treatment of a mammal.

Country Status (21)

Country Link
US (2) US8557843B2 (en)
EP (1) EP2220047B1 (en)
JP (1) JP5565841B2 (en)
KR (1) KR101572929B1 (en)
CN (1) CN103476755B (en)
AU (1) AU2008322858B2 (en)
BR (1) BRPI0820210A2 (en)
CA (1) CA2705820C (en)
DK (1) DK2220047T3 (en)
EA (1) EA018798B1 (en)
ES (1) ES2540219T3 (en)
HR (1) HRP20150583T1 (en)
HU (1) HUE025421T2 (en)
IL (1) IL205308A (en)
MX (1) MX2010005039A (en)
NZ (1) NZ585090A (en)
PL (1) PL2220047T3 (en)
PT (1) PT2220047E (en)
RS (1) RS54061B1 (en)
SI (1) SI2220047T1 (en)
WO (1) WO2009063070A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123693A1 (en) 2010-04-02 2011-10-06 Senomyx, Inc. Sweet flavor modifier
TWI610919B (en) 2011-08-12 2018-01-11 賽諾米克斯公司 Sweet flavor modifier
US9376393B2 (en) 2012-01-05 2016-06-28 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
AU2015343463A1 (en) 2014-11-07 2017-06-15 Senomyx, Inc. Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB0324270D0 (en) * 2003-10-16 2003-11-19 Univ Edinburgh Improved control of ES cell self-renewal and lineage specification, and medium therefor
AR059224A1 (en) * 2006-01-31 2008-03-19 Jerini Ag COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE
WO2007139496A1 (en) * 2006-05-30 2007-12-06 Clanotech Ab Quinoline derivatives acting as tyrosine kinase inhibitors
WO2008119771A2 (en) * 2007-03-30 2008-10-09 Clanotech Ab Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
AU2008322858B2 (en) 2013-05-02
EP2220047A2 (en) 2010-08-25
KR101572929B1 (en) 2015-11-30
CN103476755B (en) 2015-08-26
ES2540219T3 (en) 2015-07-09
DK2220047T3 (en) 2015-06-29
US20140018388A1 (en) 2014-01-16
JP2011503151A (en) 2011-01-27
AU2008322858A1 (en) 2009-05-22
MX2010005039A (en) 2010-07-30
HUE025421T2 (en) 2016-02-29
WO2009063070A3 (en) 2009-07-23
EP2220047B1 (en) 2015-05-06
US8557843B2 (en) 2013-10-15
HRP20150583T1 (en) 2015-07-31
IL205308A (en) 2015-03-31
JP5565841B2 (en) 2014-08-06
EA018798B1 (en) 2013-10-30
KR20100097158A (en) 2010-09-02
CA2705820C (en) 2016-06-07
CN103476755A (en) 2013-12-25
US20110053976A1 (en) 2011-03-03
PL2220047T3 (en) 2015-08-31
RS54061B1 (en) 2015-10-30
EA201000803A1 (en) 2011-02-28
US8957092B2 (en) 2015-02-17
WO2009063070A2 (en) 2009-05-22
SI2220047T1 (en) 2015-07-31
PT2220047E (en) 2015-07-30
NZ585090A (en) 2011-09-30
IL205308A0 (en) 2010-12-30
CA2705820A1 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
BRPI0815709A2 (en) composition, pharmaceutical composition, and use of a compound.
BRPI0821115A2 (en) Aminotriazole-derived compound, drug, pharmaceutical composition and use of compound
BRPI0810696A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
BRPI0919942A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
BRPI0907562A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI0921375A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI0716171A2 (en) compound, pharmaceutical composition and use of a compound.
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
BRPI0810354A2 (en) COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD OF TREATING A PAIN DEVICE
BRPI0922475A2 (en) compound, pharmaceutical composition, method for treating cancer, and use of a compound.
BRPI0917579A2 (en) compound, pharmaceutical composition, methods, and use of a compound
BRPI1007018A2 (en) compound, pharmaceutical composition, and use of a compound.
BRPI0820474A2 (en) method of treating a disease, use of compound, and, compound
BRPI1008906A2 (en) compound, pharmaceutical composition, and use of a compound.
BRPI0906576A2 (en) Pharmaceutical composition, kit, use of a compound, and therapeutic agent for cancer
BRPI0820568A2 (en) Compound, pharmaceutical composition, use of a compound or pharmaceutical composition, and method of treating a human or animal
BRPI0921879A2 (en) compound, pharmaceutical composition, and use of a compound
BR112012022879A2 (en) compound, pharmaceutical composition, compound use and treatment method
BRPI0907976A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease
BRPI0907974A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease
BRPI0912539A2 (en) compound, pharmaceutical composition, method for treating a disease, and use of the compound.
BRPI0810019A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
BRPI0908635A2 (en) compound, pharmaceutical composition and cancer treatment method
BRPI0906937A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI0812942A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]